INTRODUCTION

Lambert-Eaton myasthenic syndrome (LEMS) is
a rare autoimmune disorder caused by pathogenic autoantibodies directed against presynaptic voltage-gated Ca v 2.1 (P/Q type) calcium ion channel (VGCC) at the neuromuscular junction (NMJ) [1, 2] . It is clinically characterized by limb girdle weakness, increased fatigability, depressed tendon reflexes, and autonomic changes. The decreased calcium influx prevents sufficient release of acetylcholine (ACh) from the nerve terminals, subsequent stimulation of the post-synaptic membrane, and attenuates normal muscle contraction [3] [4] [5] . LEMS is estimated to affect 1:100,000 people in the European community [6] with an incidence of 0.48 to 0.75 per million [7] . In a study from South Holland, Wirtz et al. [7] found a LEMS prevalence of 2.3 per million and an annual incidence rate of 0.5 per million. The true incidence of LEMS is unknown. LEMS is reported to be associated with cancer (paraneoplastic form) in more than 50% of cases, with small cell lung cancer (SCLC) being the most frequently observed associated cancer.
The reported percentage of newly diagnosed LEMS cases associated with small SCLC ranges from 40% to 70% [7] [8] [9] . The prevalence of LEMS in patients with SCLC is estimated to be approximately 3% [10] . The low prevalence relative to incidence reflects the poor survival of LEMS patients with the paraneoplastic type of disease, and specifically the poor survival of patients with SCLC. The clinical manifestations of LEMS often precede the detection of an underlying carcinoma. The associated cancer is usually discovered within the first 2 years after the onset of LEMS and, in almost all cases, within 4 years [11] . LEMS is diagnosed based on the often suggestive clinical presentation, electrophysiological studies, testing for Ca v 2.1 P/Q-type VGCC autoantibodies, and through clinical evaluation (diagnostic considerations are described further in the ''Discussion'').
Besides the muscular weakness, LEMS is associated with signs of autonomic dysfunction such as dry mouth, constipation, and erectile dysfunction. Activities associated with daily functioning, e.g., climbing stairs without support, rising from a low sitting or squatting position, cycling, are typically affected mildly or moderately [12] . The onset of symptoms, typically at C40 years of age in patients with cancer (median age 60 years), and between 20 and 50 years of age in those without (median age 35 years), is usually gradual and insidious [13] . Rarely, respiratory function may be impaired to the extent of requiring mechanical ventilation.
LEMS EU Registry: Background and Objectives
The European Federation of Neurological Societies (EFNS) has published guidelines from two different task forces [14] [15] [16] The purpose of the present article is to provide a first interim report on the demographics and clinical characteristics of the accrued patient population at the time of baseline enrollment into the registry. Follow-up data for patients will continue to be accrued and will be reported at a later date. The registry is sponsored by BioMarin Pharmaceutical Inc.
(Novato, CA, USA). Information on health status was obtained periodically using the EuroQoL 5D (EQ-5D), a widely employed health status questionnaire [26] . The EuroQoL 5D assesses an individual's daily functioning via an Investigator's rating of a patient's ability to perform each of 12 activities as either normal/as expected or reduced/limited.
METHODS
The evaluation of treatment safety will appear in future reports and will include analyses of adverse events, concomitant medications, and clinical laboratory tests.
Data Analysis
The database used for analysis consisted of all available data for any assessments that were Assessment data are summarized using descriptive methods only using means, standard deviations (SD), medians, quartiles, and ranges (min, max). Due to the observational and non-interventional nature of the registry program, no attempts will be made to perform inferential statistical evaluation. When statistical data are presented as pooled data, data will be combined from all available patients in the four treatment groups.
RESULTS
Registry Population
A total of 69 patients have been enrolled into the LEMS registry thus far (Germany n = 30; Spain n = 0; Italy n = 22; France n = 17). At time of enrollment, patients were receiving Firdapse (n = 30), 3,4-DAP (n = 15), Other Treatments (n = 16), or Unknown Treatments (n = 8).
Four patients have been discontinued from the registry. Three patients, all who had received 3,4-DAP, were treated as discontinued from the registry due to death. Two deaths were the result of cardiac arrest. The third death was the result of renal failure followed by multi-organ failure. In all 3 cases, death was reported as unrelated to 3,4-DAP and unrelated to other LEMS medications. Another patient who had also received 3,4-DAP withdrew from the registry due to moving to another city and has been lost to follow-up. Pack-years for current smokers 
Population Demographics and Other Characteristics
Diagnostic Characteristics and Clinical
Status of Patients at Enrollment
The CMAP amplitude parameter assessed during EMG evaluation, along with autoantibody testing (Ca v 2.1 P/Q-type VGCC) and a clinical evaluation of symptoms, were the primary methods used to confirm the diagnosis of LEMS.
Results were positive (?ve) at baseline for 19 of the 21 patients for whom VGCC data were available in the overall registry population. 
Electrophysiology
The mean percent increment and decrement values and the individual values for the patients for whom EMG testing was available near the time (±1 month) of enrollment into the registry indicated abnormality in neuromuscular functioning for most patients using the standard criteria, i.e., a decrement of [10% and/or a marked increment relative to rest.
Quantitative Myasthenia Gravis Questionnaire
Results for the raw QMG Total Score and %Standardized QMG Total Score by treatment group at enrollment are summarized in Table 4 . clinical studies evaluating the efficacy of 3,4-DAP. This is to exclude patients who have insufficient disease severity from participation [28] .
Reflexes and Muscle Strength
Patients who had available data at enrollment showed reduced reflexes at the following sites tested: 76.0% of patients were noted to have a reduced reflex at the knee (38/50), 80% at the Achilles (10/50), 64% at the biceps (18/50), and 67% at the triceps. Muscle strength for patients who had available data was generally good with the great majority of patients in all 4 treatment groups evaluated as a 4-movement against partial resistance, or as a 5-full strength, in all 12 muscles or muscle groups evaluated. Within these muscle strength response categories, no specific patterns of differences between treatment groups were apparent. Five patients scored a 2-movement with gravity eliminated, indicating abnormal muscle weakness. Of these 5 patients, 3 were in the Other LEMS treatments group and 2 were in the Firdapse treatment group.
Ataxia
The majority of patients were assessed as negative for ataxia at enrollment for each of the six standard movement tests administered, both overall and within the four treatment groups. However, there were several exceptions; 4 of the 8 patients (50%) in the 3,4-DAP group were noted as positive for ataxia during the line walk test, 5 of the 10 patients (50%) in the 3,4-DAP group were positive on the heel-to-knee test, and 2 of the 3 patients (66.7%) in the Unknown Treatment group were positive on the line walk test.
Autonomic Nervous System
The most frequent sign of autonomic abnormality was dry mouth, noted for 51.1% of patients who had available data, followed by abnormal pupil reflex (24%), abnormal bladder function (24%), constipation (21%), dry eyes (12%), orthostatic intolerance (10%), and erectile dysfunction/impotence (for 22% of males). Electrophysiological testing protocols must be adhered to, however, to achieve consistency and reliability of results across clinical centers.
CMAP may be used to periodically monitor the clinical effectiveness of treatment over the long-term. Test kits for assay of Ca v 2.1 P/Q-type VGCC autoantibody titers are commercially available.
Males and females were equally represented in this study population and there was a wide range of ages at enrollment (27- in patients with LEMS is higher than expected by chance. When it occurs, it is usually associated with carcinoma [30] . Cerebellar degeneration leading to ataxia can be paraneoplastic in origin, a non-metastatic complication of carcinoma. It is thought that this process is mediated by antibody response against tumor antigens, especially against the Ca v 2.1 P/Q-type VGCCs which are highly expressed in the cerebellum, leading to cerebellar degeneration [31] . It is recommended that patients with LEMS be periodically assessed and monitored for the onset of ataxia which can indicate the presence of a degenerative cerebellar process of paraneoplastic origin. Approximately 50-60% of patients in the registry have an underlying tumor (paraneoplastic form), but LEMS can also occur in the absence of cancer (idiopathic form). The prevalence of the two forms is similar but the incidence of the paraneoplastic form is much higher [32] . This latter form is most commonly associated with SCLC but can also result from other malignancies [8] 
Treatment Characteristics
Since most patients had been receiving LEMS treatments to improve neuromuscular and autonomic functioning for at least a short time by enrollment, it is likely that the picture of mild-to-moderate impairment for most patients had already reflected some degree of improvement resulting from initiation of treatment. Forty-five of the 69 patients in the registry (65%) were on either Firdapse (n = 30) or 3,4-DAP base (n = 15) at registry enrollment.
Forty patients (58%) were on Firdapse at some point, either before, during or after enrollment. 
CONCLUSIONS
The LEMS EU registry will continue to enroll patients and periodically report on the clinical outcomes of this patient population. 
